Ticker
ACRS

Price
18.22
Stock movement up
+0.91 (5.26%)
Company name
Aclaris Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Diagnostics & Research
Markedsverdi
1.21B
Ent verdi
1.22B
Pris/omsetning
188.46
Pris/bok
6.73
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
22.86%
3 års avkastning
162.27%
5 års avkastning
-6.66%
10 års avkastning
-
Sist oppdatert: 2022-08-25

UTBYTTE

ACRS betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning188.46
Pris til bok6.73
EV i forhold til salg190.01

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall66.58M
EPS (TTM)-1.32
FCF per aksje (TTM)-1.00

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)6.44M
Bruttofortjeneste (TTM)2.93M
Driftsinntekter (TTM)-80.10M
Netto inntekt (TTM)-80.90M
EPS (TTM)-1.32
EPS (1 år fremover)-1.45

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)45.46%
Driftsmargin (TTM)-1244.38%
Fortjenestemargin (TTM)-1256.80%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter36.34M
Netto fordringer633.00K
Samlede omløpsmidler190.88M
Goodwill0.00
Immaterielle eiendeler7.03M
Eiendom, anlegg og utstyr0.00
Sum eiendeler226.53M
Leverandørgjeld8.12M
Kortsiktig/nåværende langsiktig gjeld716.00K
Sum kortsiktig gjeld16.73M
Sum gjeld46.33M
Aksjonærenes egenkapital180.20M
Netto varige driftsmidler173.17M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-60.87M
Kapitalutgifter (TTM)524.00K
Fri kontantstrøm (TTM)-61.40M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-44.89%
Avkastning på eiendeler-35.71%
Avkastning på investert kapital-44.72%
Kontantavkastning på investert kapital-33.94%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning17.53
Daglig høy18.22
Daglig lav17.35
Daglig volum382K
Tidenes høyeste32.99
1 år analytikerestimat34.80
Beta0.61
EPS (TTM)-1.32
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon31 Oct 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACRSS&P500
Nåværende prisfall fra toppnotering-44.77%-12.18%
Høyeste prisfall-97.73%-56.47%
Dato for høyeste fall18 Mar 20209 Mar 2009
Gj.snittlig fall fra topp-52.08%-11.38%
Gj.snittlig tid til ny topp72 days12 days
Maks tid til ny topp1351 days1805 days
SELSKAPSOPPLYSNINGER
ACRS (Aclaris Therapeutics Inc) company logo
Markedsverdi
1.21B
Markedsverdi kategori
Small-cap
Beskrivelse
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Ansatte
72
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Neal S. Walker
Land
USA
By
Malvern
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
27. september 2022
Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders have seen the share price descend 10% over the month. But over...
15. september 2022
WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
30. august 2022
WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
25. august 2022
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
5. august 2022
Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
3. august 2022
•Appointed Douglas Manion, M.D., FRCP (C), as President and COO •Initiated Phase 2a Study Activities for Psoriatic Arthritis WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (N...
3. august 2022
Appoints Douglas Manion, M.D., FRCP (C), as President and COO WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focuse...
1. august 2022
Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
15. juli 2022
Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
8. juli 2022
Neste side